A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device

Healthy Volunteers Clinical Trial

Official title:

A PHASE 1, OPEN-LABEL, RANDOMIZED, 4-PERIOD, 2-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF MARSTACIMAB (PF-06741086) PREFILLED SYRINGE DEVICE AND PREFILLED PEN DEVICE FOLLOWING SUBCUTANEOUS ADMINISTRATION IN HEALTHY ADULT MALE PARTICIPANTS

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04832139
• Other study ID #: B7841009
• Secondary ID: 2020-004369-38
• Status: Terminated
• Phase: Phase 1
• Start date: March 30, 2021
• Est. completion date: November 22, 2021

Study information

• Verified date: July 2022
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal in this study is to show that there are not significant differences in biologic activity of the study drug when administered using either the prefilled pen and prefilled syringe.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: November 22, 2021
• Est. primary completion date: November 22, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Male participants who are overtly healthy as determined by medical evaluation

• Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

• BMI of 17.5 to 30.5 kg/m2; and a total body weight = 50 kg (110 lb).

• Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, dermatological, or allergic disease

• Any condition possibly affecting drug absorption (eg, conditions affecting SC administration)

• Previous or current treatment for and/or history of coronary artery diseases, venous or arterial thrombosis, or ischemic disease.

• History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb or HCVAb

• Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior, laboratory abnormality or COVID-19 related condition that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study

• Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention

• Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).

• A positive urine drug test at screening and/or admission

• Screening supine BP =140 mm Hg (systolic) or =90 mm Hg (diastolic)

• Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results

• Participants with ANY of the following abnormalities in clinical laboratory tests at screening:

• AST or ALT level =1.5 × ULN;

• Total bilirubin level =1.5 × ULN.

• An estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m2 based on the CKD-EPI equation.

• Resistance to activated protein C (or Factor V Leiden mutation), prothrombin 20210 mutation, antithrombin III deficiency, protein C deficiency, or protein S deficiency.

• Presence of Lupus anticoagulant anti-cardiolipin antibodies (IgG, IgM or IgA)

• High sensitivity C-reactive protein (hsCRP) above the upper limits of normal

• Abnormal hematology values as defined by the following laboratory tests at Screening and/or admission:

• Platelet count <100,000/uL

• Hemoglobin level <10 g/dL

• A positive COVID-19 test.

• History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening

• Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day

• Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.

• Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of the protocol

• Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Marstacimab PFP
300 milligrams (mg) subcutaneous injection marstacimab PFP
• Marstacimab PFS
300 mg subcutaneous injection of marstacimab PFS

Locations

Country	Name	City	State
Belgium	Brussels Clinical Research Unit	Brussels	Bruxelles-capitale, Région DE

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under the plasma concentraiton time Curve from time zero extrapolated to infinite time (AUCinf)		Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
Primary	Maximum observed plasma concentration (Cmax)		Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
Secondary	Area under the concentration time curve from time 0 to time of last quatifiable concenteration		Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
Secondary	Time for Cmax		Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
Secondary	Apparent clearance after subcutaneous dose		Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
Secondary	Apparent volume of distribution after subcutaneous dose		Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
Secondary	Terminal half-life after subcutaneous dose		Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose
Secondary	Incidence of clinically significant laboratory value abnormalities		Baseline through the end of study, approximately 161 days
Secondary	Incidence of anti-drug antibody against marstacimab		From Day 1, Period 1 through Day 21, Period 4 over a total of 84 days
Secondary	Incidence of Adverse Events		Baseline through the end of study, approximately 161 days
Secondary	Incidence of neutralizing antibody against marstacimab		From Day 1, Period 1 through Day 21, Period 4 over a total of 84 days
Secondary	Incidence of Serious Adverse Events		Baseline through the end of study, approximately 161 days

External Links

•   To obtain contact information for a study center near you, click here.